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Some individuals infected with dengue virus develop dengue hemorrhagic fever (DHF), a viral hemorrhagic
disease characterized by a transient period of localized plasma leakage. To determine the importance of
vascular endothelial growth factor A (VEGF-A) in this syndrome, we compared plasma levels of VEGF-A and
the soluble forms of its receptors in patients with DHF to patients with dengue fever (DF), a milder form of
dengue virus infection without plasma leakage. We observed a rise in the plasma levels of free, but not total
VEGF-A in DHF patients at the time of plasma leakage. This was associated with a decline in the soluble form
of VEGF receptor 2 (VEGFR2) and VEGF-soluble VEGFR2 complexes, but not the soluble form of VEGFR1.
The severity of plasma leakage in patients inversely correlated with plasma levels of soluble VEGFR2. In vitro,
dengue virus suppressed soluble VEGFR2 production by endothelial cells but up-regulated surface VEGFR2
expression and promoted response to VEGF stimulation. In vivo, plasma viral load correlated with the degree
of decline in plasma soluble VEGFR2. These results suggest that VEGF regulates vascular permeability and
its activity is controlled by binding to soluble VEGFR2. Dengue virus-induced changes in surface and soluble
VEGFR2 expression may be an important mechanism of plasma leakage in DHF.
Plasma leakage is a hallmark of a number of severe viral
diseases, including dengue hemorrhagic fever (DHF), hanta-
virus pulmonary syndrome, and hemorrhagic fever with renal
syndrome (17, 33, 34). Infection with any of the four serotypes
of dengue virus can lead to DHF, a syndrome characterized by
a sudden and transient period of localized plasma leakage
manifesting as fluid accumulation in the pleural and/or abdom-
inal cavity at the time of defervescence (4). Only 3 to 5% of
dengue virus-infected individuals develop DHF, and the risk of
developing this condition increases significantly in those pre-
viously infected with another serotype of dengue virus (sec-
ondary infection) (8). Plasma leakage in DHF generally lasts
no more than 48 h and is usually followed by rapid, complete
recovery. Consistent with the clinical course, plasma leakage in
DHF occurs with a relative lack of tissue inflammation, sug-
gesting that a transient change in factors that regulate vascular
permeability in the physiological state may be the mechanism
of plasma leakage in this disease (7).
Although elevated levels of cytokines with a permeability-
enhancing effect, such as interferons (IFNs), interleukin-2 (IL-
2), IL-8, and tumor necrosis factor alpha, have been reported
in DHF, the relative role of these cytokines in plasma leakage
is not known (20, 36). A recent study has demonstrated ele-
vated levels of vascular endothelial growth factor A (VEGF-
A), the most potent permeability-enhancing cytokine, in DHF
(44). At least two VEGF receptors are expressed on endothe-
lial cells; both are transmembrane receptor tyrosine kinases,
namely, VEGFR1 or Fms-like tyrosine kinase 1 (Flt-1) and
VEGFR2 or KDR (kinase insert domain receptor) (40).
VEGFR1 is expressed on cell types other than endothelial
cells, notably macrophages, while VEGFR2 is expressed pri-
marily on endothelial cells and their progenitors (35, 38).
VEGF binding to VEGFR2 on endothelial cells results in
phosphorylation of the receptors, changes in endothelial cell
morphology, increased permeability, and cell proliferation
(15). The role of VEGFR1 in enhancing permeability is still
controversial. A well-characterized soluble form of VEGFR1
(sVEGFR1), a product of alternatively spliced mRNA, has
been shown to bind VEGF and inhibit its activity in vivo (26,
31). In contrast, little is known about the biosynthetic pathway
of the recently reported soluble form of VEGR2 (sVEGFR2)
and about its functions (11).
In this study, we compared plasma levels of VEGF and its
soluble receptors throughout the course of the illness in pa-
tients with DHF to those of patients with dengue fever (DF),
a milder form of dengue virus infection without plasma leak-
age. We found evidence suggesting that VEGF participates in
the regulation of vascular permeability and its activity is con-
trolled by a soluble form of its receptor, VEGFR2. Our in vitro
results also support a novel mechanism by which dengue virus
might modify vascular permeability by altering the production
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of sVEGFR2 and the expression of surface VEGFR2 on en-
dothelial cells.
MATERIALS AND METHODS
Collection of specimens. Plasma samples were collected between 1994 and
2001 from children with acute febrile illnesses recruited for a prospective study
at the Queen Sirikit National Institute of Child Health, Bangkok, Thailand, that
was previously described (25). Children with febrile illness without an obvious
source of infection were enrolled during the first 3 days of illness and observed
in the hospital until 1 day after defervescence. Blood samples were collected
daily during hospitalization and at a follow-up visit during convalescence (ap-
proximately 4 to 6 days after discharge) for hematocrit and platelet count de-
terminations and serologic and virologic testing. On the day after defervescence,
a right lateral decubitus chest radiograph was obtained to detect pleural fluid.
Subjects were categorized as having DF or DHF on the basis of the World
Health Organization criteria (4). For the present study, archived frozen plasma
samples from 22 DF and 23 DHF patients whose duration of stay was at least 5
days were analyzed. There were 17, 16, 10, and 2 cases of dengue 1, 2, 3, and 4
virus infections, respectively. These were classified serologically into 9 cases of
primary dengue virus infection and 36 cases of secondary dengue virus infection.
This study was approved by the Institutional Review Boards of the Thai Ministry
of Public Health, the U.S. Army Surgeon General’s Office, and the University of
Massachusetts Medical School. Written consent was obtained from the parents
or legal guardian of each participant.
ELISA. Levels of VEGF, sVEGFR1, and sVEGFR2 in plasma were measured
with sandwich enzyme-linked immunosorbent assay (ELISA) kits (R&D Sys-
tems). The antibodies used in these ELISAs do not cross-react with molecules
related to the assayed ligand within the range of concentrations reported in this
study (manufacturer’s [R&D Systems] product information and unpublished
data). To dissociate VEGF-receptor complexes, plasma samples were incubated
with an equal volume of 1.5 M glycine for 1 h at 37°C. Tris-HCl (1.5 M, pH 9.7)
was then added to the mixture, and it was incubated at room temperature for 15
min. The samples were then used in the VEGF sandwich ELISA with the
modification that the recombinant VEGF used to generate the standard curve
was treated in a fashion similar to that used for the samples. Phosphorylated
VEGFR2 was measured with an ELISA kit (R&D Systems). Dengue viral an-
tigen was measured in a sandwich ELISA with a monoclonal antibody (3H5)
specific for dengue 2 virus envelope protein as the capture antibody and a
horseradish peroxidase-conjugated polyclonal human anti-flavivirus antibody as
the detecting antibody as previously described (28).
Detection of VEGF bound to sVEGFR2. sVEGFR2 in plasma samples was
captured by incubating plasma samples overnight at 4°C in wells coated with
antibody specific to VEGFR2. Samples were removed, and the wells were
washed once with phosphate-buffered saline–Tween. To dissociate the captured
sVEGFR2 from the associated VEGF molecules, 50 l of assay diluent and 50
l of 1.5 M glycine were added to each well and incubated at 37°C for 1 h. Fifty
microliters of Tris HCl (1.5 M, pH 9.7) was then added to each well. The
amounts of dissociated VEGF and sVEGFR2 in the mixtures were then mea-
sured by the corresponding sandwich ELISA with similarly treated recombinant
antigens to generate standard curves. In pilot experiments with mixtures of
recombinant VEGFR2 and VEGF at various molar ratios, we found that VEGF
alone did not give a signal in this assay (unpublished data). The amount of VEGF
bound to sVEGFR2 in plasma samples was calculated by the following formula:
plasma VEGF that bound to sVEGFR2 (picograms per milliliter) plate-bound
VEGF (picograms per milliliter)  plasma sVEGFR2 (picograms per milliliter)/
plate-bound sVEGFR2 (picograms per milliliter).
Infection of endothelial cells. Human umbilical vein endothelial cells
(HUVEC) were grown and maintained as instructed by the manufacturer (Cam-
brex). Cells were used up to passage 10 for these studies. Dengue type 2 virus
strain 16681 was grown in the C6/36 mosquito cell line, and titers were deter-
mined on LLC-MK2 cells as previously described (37). Where indicated, the
virus was inactivated by UV irradiation with a germicidal lamp (60 min); absence
of viable virus was confirmed by plaque assay. HUVEC were infected with live or
inactivated dengue virus at a multiplicity of infection (MOI) of 5 unless otherwise
indicated or were exposed to supernatant of uninfected C6/36 cells as a control.
In some experiments, HUVEC were infected with live or inactivated dengue
virus in the presence of a 1:25,000 dilution of immune plasma (neutralizing titer
of 1:486 against dengue 2 virus). HUVEC supernatants were collected at the
indicated time points and assayed for sVEGFR2 by ELISA. Cells were collected
and stained with antibody to VEGFR2 (R&D Systems) and analyzed with a
FACScalibur flow cytometer (Becton Dickinson). Solubilized HUVEC mem-
brane fractions were prepared in 20 mM Tris Cl (pH 8.0) with 1% NP-40 and
protease inhibitor cocktail (Sigma) and analyzed for VEGFR2 by ELISA. Where
indicated, HUVEC were treated with recombinant VEGF (R&D Systems) at 1
ng/ml for 5 min; cells were then lysed, and the amounts of phosphorylated
VEGFR2 were analyzed by ELISA (R&D Systems).
Measurement of plasma viral load. RNA was extracted from 100 l of plasma,
and viral RNA genome content was measured with a fluorogenic reverse tran-
scription-PCR as previously described (22). cDNA of the dengue virus 3 non-
coding region was cloned into a pUC vector, and serial dilutions of the plasmid
were used to construct a standard curve for each viral serotype. Plasma dengue
virus RNA levels were expressed as genome equivalent cDNA copies per milli-
liter. All unknown samples and controls were assayed in triplicate. The ABI gene
detection system 7700 (Perkin-Elmer Applied Biosystems) was used for PCR
cycling amplification, data collection, and analysis.
Statistical analysis. For statistical analysis, the day of defervescence, corre-
sponding to the usual period of plasma leakage in DHF, was defined as fever day
0 and the days before (fever days 1, 2, etc.) and after (fever days 1, 2, etc.)
were numbered sequentially. Continuous variables were analyzed by Kolmogorov-
Smirnov’s test for normality of distribution. Normally distributed variables were
compared between groups with Student’s t test. A paired t test was used to
analyze differences in variables of individuals at different time points or related
variables within individual samples. A P value of less than 0.05 was considered to
indicate statistical significance. All tests were two sided. Associations between
continuous variables were calculated by either parametric Pearson correlation or
nonparametric Spearman correlation.
RESULTS
Plasma VEGF in patients with DF and DHF. We first mea-
sured levels of VEGF in serial plasma samples from subjects
with acute dengue illness enrolled in a prospective cohort
study, including a group with DHF and a comparable group
with DF. The mean levels of plasma VEGF in DHF patients
increased during illness, with the highest mean values observed
on the day of defervescence (fever day 0; Fig. 1A). The levels
of VEGF were significantly higher in subjects with DHF than
in those with DF on fever days 1 (1 day prior to deferves-
cence), 0, and 1 (1 day after defervescence).
Previous studies have shown that VEGF bound to a soluble
form of its receptor, VEGFR1, cannot be detected with this
ELISA system (23). Therefore, the differences in free VEGF
levels might reflect differences in total (bound plus free)
VEGF or alternatively might reflect changes in relative bind-
ing. To measure total VEGF, we dissociated protein complexes
by incubating plasma samples with 1.5 M glycine prior to
ELISA. In contrast to free VEGF levels, total VGEF levels
were not different between DHF and DF patients (Fig. 1B). At
the follow-up visit, free VEGF levels had declined significantly
in subjects with DHF, and neither free nor total VEGF levels
were significantly different between DF and DHF subjects
(P  0.93 for free VEGF, P  0.48 for total VEGF, Fig. 1A
and B). The levels of free VEGF on fever day 0 were signifi-
cantly lower than the levels of total VEGF in the same plasma
samples from DF patients but not in those from DHF patients
(P 0.045, by paired t test, Fig. 1C), indicating the presence of
the bound form of VEGF in DF, but not DHF, patients.
During convalescence, free VEGF levels were lower than total
VEGF in both DF and DHF patients, suggesting reemergence
of the bound form of VEGF in DHF patients at this time point
(Fig. 1C).
Different profiles of soluble VEGF receptors in DF and
DHF patients. A potential candidate for a VEGF-binding
molecule is its soluble receptor. A soluble form of VEGFR1
(sVEGFR1 or sFlt-1) is generated by differential splicing of
VEGFR1 mRNA (26). We measured plasma levels of solu-
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ble VEGFR1 and observed a sharp rise in sVEGFR1 levels in
DHF patients on fever day 0 when plasma leakage occurred (Fig.
2A), followed by a decline during convalescence.
Since the increase in sVEGFR1 did not provide an expla-
nation for the increase in free VEGF in DHF cases, we next
determined the plasma levels of sVEGFR2 (11). The levels
of plasma sVEGFR2 were more than 20-fold higher than
sVEGFR1 levels (Fig. 2B). In contrast to the changes in
sVEGFR1 levels, sVEGFR2 levels in DHF patients declined
dramatically toward the time of plasma leakage while the levels
FIG. 1. VEGF levels in serial plasma samples from DHF and DF patients. (A) Mean levels of VEGF in plasma samples from DHF (n  23,
filled symbols) and DF (n  22, open symbols) patients over the course of the illness and at convalescence (4 to 6 days after discharge). Error bars
represent standard errors of each group of samples at the indicated time points. P values are for comparisons between DF and DHF patients.
(B) Mean total VEGF in plasma samples from DF (open symbols) and DHF (filled symbols) patients. NS, no statistically significant difference.
(C) Comparisons between free and total VEGF levels within individual plasma samples from DF and DHF patients at fever day 0 and during
convalescence.
FIG. 2. sVEGFR1 and sVEGFR2 in DF and DHF patients. (A) Levels of sVEGFR1 in plasma samples from DHF (n  23, filled symbols)
and DF (n  22, open symbols) patients over the course of illness. Error bars represents means  standard errors. P values are for comparisons
between DF and DHF patients. (B) Levels of sVEGFR2 in plasma samples from DHF and DF patients. P values are for comparisons between
DF and DHF patients. Horizontal brackets indicate P values derived from paired Student t tests comparing levels in the same individuals on
different days. (C) Levels of VEGF bound to VEGFR2 in plasma of DF and DHF patients on fever days 3 and 1 and during convalescence.
The vertical bracket indicates P values derived from a Student t test comparing DF and DHF patients. Horizontal brackets indicate P values derived
from paired Student t tests comparing levels on different days.
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in DF patients remained relatively unchanged (Fig. 2B). The
mean level of sVEGFR2 in DHF patients became significantly
lower than in DF patients 1 day prior to defervescence and
later (Fig. 2B). During convalescence, the levels of sVEGFR2
in DHF patients increased and approached the levels in DF
patients (Fig. 2B).
The progressive decline of sVEGFR2 levels and the con-
comitant increase in unbound VEGF in DHF patients sug-
gested that sVEGFR2 may be the molecule that bound VEGF
in vivo. To directly measure VEGF bound to sVEGFR2, we
established a capture assay in which plasma sVEGFR2 was
captured with a plate-bound antibody and the amount of cap-
tured sVEGFR2 and associated VEGF was quantified by
ELISA. The mean level of VEGF bound to sVEGFR2 in DHF
patients was significantly lower than that in DF patients 1 day
after defervescence (46  13.7 versus 173  39.6 pg/ml, P 
0.006, Fig. 2C). The levels of sVEGFR2-bound VEGF in-
creased during convalescence in both DF and DHF patients.
Plasma leakage in DHF patients often leads to the forma-
tion of pleural effusion. To evaluate the biological relevance of
sVEGFR2 in the regulation of vascular permeability, we ana-
lyzed the correlation between the levels of plasma sVEGFR2
on fever day 1 and the amount of pleural fluid measured as
a pleural effusion index, an indicator of the severity of plasma
leakage. There was an inverse correlation between plasma
sVEGFR2 levels and the amount of pleural fluid measured at
the time of plasma leakage (r  0.562, P  0.001, by Spear-
man’s analysis, Fig. 3A). In addition, the amount of pleural
fluid showed a direct correlation with plasma levels of VEGF
(r  0.396, P  0.008, by Spearman’s analysis, Fig. 3B). Taken
together, these findings support the role of sVEGFR2 in the
regulation of VEGF activity and vascular permeability in vivo.
Dengue virus alters the production of soluble and surface
VEGFR2 by endothelial cells. Several studies have demon-
strated greater viral loads in patients with DHF compared to
those with DF, suggesting that direct viral effects, or the mag-
nitude of the host response to the virus, may be critical in
determining disease severity (29, 45). Dengue virus has been
shown to infect endothelial cells in vitro (5). A recent study has
demonstrated dengue virus antigen in endothelial cells in vivo
although the dengue virus genome was not detected in these
cells (24). We postulated that exposure to dengue virus may
alter the expression of soluble and surface VEGFR2 by endo-
thelial cells, resulting in changes in vascular permeability.
We exposed HUVEC to dengue 2 virus and measured the
production of sVEGFR2 and VEGFR2 surface expression.
Infection with dengue virus resulted in suppression of
sVEGFR2 levels after 72 h of infection but not at earlier time
points (Fig. 4A). This was not due to cell death since no
cytopathic effects were observed in these cells. Furthermore,
this effect was specific to sVEGFR2 since the levels of
sVEGFR1 in the culture supernatants were not altered by
dengue virus infection (Fig. 4B). The down-regulation of
sVEGFR2 required live virus and was associated with an in-
crease in cell surface VEGFR2 expression. (Fig. 4A and C).
Exposure to live virus resulted in increased surface VEGFR2
expression in both infected and uninfected cells in the same
culture, indicating that viral or host-derived factors, rather
than intracellular viral replication, mediate this effect (Fig.
4D). Consistent with the flow cytometry findings, the levels of
VEGFR2 in the membrane fraction of an infected HUVEC
monolayer were higher than those of uninfected cells (353  8
pg/ml [infected cells] versus 213  24 pg/ml [uninfected cells],
P  0.006). The suppression of sVEGFR2 production ap-
peared to be viral dose dependent, as infection at a high MOI
of 10 but not at a low MOI of 2 resulted in a significant
decrease in sVEGFR2 levels (Fig. 4E).
To evaluate the relationship between virus and sVEGFR2 in
vivo, we analyzed the correlation between the plasma viral load
and sVEGFR2 levels. The plasma viral load was measured in
samples collected 2 days prior to defervescence because circu-
lating virus rapidly declined after this time point. The plasma
viral load of samples from fever day 2 showed no correlation
with sVEGFR2 levels in the same samples, calculated as per-
FIG. 3. Correlations between the severity of plasma leakage and plasma sVEGFR2 and free VEGF levels. (A) Linear regression analysis
revealed an inverse correlation between the levels of sVEGFR2 on fever day 1 and the pleural effusion index (PEI), a semiquantitative
measurement of the severity of pleural effusion. A right lateral decubitus chest radiograph was obtained on fever day 1, and the index was
calculated as follows: 100  (maximum width of right pleural effusion)/(maximum width of right hemithorax). (B) Correlations between the levels
of free VEGF and the amount of pleural fluid.
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cent decline from the levels on fever day 3 (r  0.022, P 
0.978, by Pearson’s analysis). However, it showed a significant
correlation with the decline in sVEGFR2 levels 3 days later,
during the period of plasma leakage (r  0.774, P  0.001 by
Pearson’s analysis, Fig. 5). This result suggests that a greater
viral load is associated with a more severe decline in sVEGFR2
levels, with a lag period between the two events.
Dengue virus immune plasma enhances viral infection, sup-
presses sVEGFR2 production, and promotes VEGFR2 signal-
ing in HUVEC. Prior exposure to dengue virus is a major risk
factor for the development of plasma leakage in subsequent
dengue virus infections (8). One of the proposed mechanisms
is the presence of nonneutralizing antibodies, which facilitate
viral uptake and replication (27). To determine whether den-
gue virus-specific antibodies can enhance infection of endothe-
lial cells and the subsequent suppression of sVEGFR2 produc-
tion, we inoculated HUVEC with virus at a low MOI of 2 in the
presence of immune plasma, which was diluted beyond its
neutralizing titer of 1:486. We observed more viral antigen but
less sVEGFR2 in culture supernatants (collected at 48 and
72 h postinfection for viral antigen and sVEGFR2 assays, re-
FIG. 4. Effects of dengue virus on soluble and cell surface VEGFR2 expression by HUVEC. (A) HUVEC were exposed to live dengue 2 virus
(DEN 2V, filled circles), UV-inactivated virus (UV DEN 2V, empty circles), or C6/36 cell supernatant as a control (C6/36 Sup, triangles). At the
time points indicated, supernatants were collected and analyzed for sVEGFR2. Data represent means (n  4)  standard deviations. P  0.001
for the comparison between cells exposed to live virus and UV-inactivated virus or C6/36 cell supernatant. (B) Levels of sVEGFR1 in supernatants
from HUVEC after a 72-h exposure to live dengue 2 virus (black bar), UV-inactivated virus (gray bar), or C6/36 cell supernatant as a control (white
bar). (C). Surface expression of HUVEC exposed to live dengue 2 virus (black bar), UV-inactivated virus (gray bar), or C6/36 cell supernatant as
a control (white bar). Staining intensity of UV-inactivated virus- and live dengue virus-exposed cells was compared against that of C6/36
supernatant-exposed cells, which is expressed as 100%. Data represent means (n  4)  standard deviations. (D) Cells exposed to live virus were
stained for dengue virus envelope antigen and cell surface VEGFR2, cells were gated on the basis of the expression of viral envelope antigen, and
the surface VEGFR2 expression of virus-infected and uninfected cells was analyzed. MFI, mean fluorescence intensity. (E) HUVEC were infected
with live dengue 2 virus at an MOI of 1 (empty circles), 2 (filled triangles), or 10 (empty triangles) or with inactivated virus (filled circles). The
levels of sVEGFR2 in the supernatants at the indicated time points were analyzed. Data represent means  standard deviations of triplicate
samples. P  0.003 for the comparison between cells infected with an MOI of 10 and cells exposed to inactivated virus.
FIG. 5. Correlations between plasma viral load and percent decline
in sVEGFR2. Linear regression analysis revealed the correlation be-
tween the percent decline in levels of sVEGFR2 on fever day 1
(compared to the levels on fever day 3) and the plasma viral RNA
from fever day 2.
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spectively) of these cells than in cells infected with virus in the
absence of immune plasma (Fig. 6A and B). We then examined
the responsiveness of these cells to VEGF stimulation by mea-
suring the levels of VEGR2 that underwent receptor phosphor-
ylation in response to VEGF treatment (1 ng/ml). More phos-
phorylated VEGFR2 was detected in HUVEC that were
inoculated with dengue virus immune complexes than in cells
treated otherwise, suggesting an enhanced response to cyto-
kine stimulation (Fig. 6C).
DISCUSSION
Plasma leakage is the central event in the pathogenesis of
DHF. Elevated levels of cytokines with permeability-enhanc-
ing effects have been reported in DHF, although their relative
importance is not known. Elevated levels of VEGF, a potent
vascular permeability-enhancing cytokine, have been previ-
ously reported in DHF patients (44). Here we demonstrated
that the increase in plasma free VEGF levels was associated
with a decrease in its soluble receptor, VEGFR2. We also
present the first evidence of VEGF binding to naturally occur-
ring sVEGFR2 in vivo, suggesting its role as a regulator of
VEGF function.
Studies of patients with preeclampsia and studies with ani-
mal models have demonstrated that VEGF activity in vivo
could be inhibited by binding to the soluble form of another
VEGF receptor, VEGFR1 (31). Several pieces of evidence in
the present study, however, implicate sVEGFR2 as the more
important regulator of VEGF effects in vivo. First, sVEGFR2
is present at much higher levels in plasma than is sVEGFR1.
The levels of sVEGFR1 observed in our patients were com-
parable to the levels reported in normal adults but were 10-fold
lower than the levels found in pregnant women, whose
sVEGFR1 was produced by the placenta (11, 31). The binding
capacity of sVEGFR1, even at peak levels in our study sub-
jects, was too low to neutralize a significant fraction of plasma
VEGF. Second, the decline in plasma sVEGFR2 and
sVEGFR2-VEGF complexes was temporally associated with
an increase in free VEGF and the onset of plasma leakage.
Third, the correlation between the amount of pleural effusion
and the decline in sVEGFR2 supports its role in modulating
VEGF effects. These results are consistent with animal studies
demonstrating that blocking of VEGF functions with an
sVEGFR2-Fc chimeric molecule reduced malignant ascitic
fluid formation (9, 21). Although VEGF forms complexes with
sVEGFR2 in vivo, it is notable that plasma free VEGF still
exists in the presence of a molar excess of sVEGFR2. This may
be due to the relatively low affinity of VEGF for binding to
VEGFR2 (35, 39). Collectively, these observations suggest that
under non-pregnancy-related conditions, sVEGFR2 binds
VEGF and regulates its activities.
The structure and the biosynthetic pathway of sVEGFR2
are not known. No alternatively spliced form of VEGFR2
mRNA encoding a soluble receptor has been reported. The
temporal association between the decline in sVEGFR2 levels
and an increase in surface VEGFR2 expression on endothelial
cells suggests that sVEGFR2 is a proteolytic product of mem-
brane VEGFR2. Inhibition of cleavage of surface receptors
may increase ligand sensitivity by increasing receptor density,
as well as decreasing inhibitory soluble receptors (3). Although
the association between the decline in sVEGFR2 and plasma
leakage, which suggests enhanced VEGF activity in vivo, is
consistent with this view, it remains to be demonstrated that
there is an up-regulation of surface VEGFR2 and enhanced
signaling through VEGFR2 in vivo during plasma leakage.
We have shown in this study that exposure of endothelial
cells to live dengue virus resulted in decreased production of
the soluble form of VEGFR2 and enhanced surface VEGFR2
expression. The correlation between plasma viral load and the
subsequent decline in sVEGFR2 levels lend support to this in
vitro finding. Previous studies have shown increased sensitivity
of endothelial cells exposed to live dengue virus to inflamma-
tory cytokine-induced changes in permeability (42). Our ob-
servations suggest a novel mechanism by which viral factors (or
host factors triggered by virus) may regulate the cleavage of
surface VEGFR2, resulting in changes in soluble and surface
FIG. 6. Effects of dengue virus immune plasma on viral replication, sVEGFR2 production, and VEGF signaling in HUVEC. HUVEC were
exposed to live dengue 2 virus with or without diluted immune plasma or to inactivated virus in the presence of immune plasma. Viral envelope
protein (A) and sVEGFR2 (B) in the supernatants were measured 48 and 72 h after viral exposure, respectively. Cells were then treated for 5 min
with recombinant VEGF (1 ng/ml), and the amount of phosphorylated VEGFR2 was measured (C). Data represent means  standard deviations.
n  4 per group. O.D., optical density.
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VEGF receptors and, consequently, changes in vascular per-
meability. Although our findings suggest a model in which viral
infection of endothelial cells leads to changes in membrane
and sVEGFR2 (Fig. 7), definitive in vivo evidence of dengue
virus infection of endothelial cells has been lacking (24).
The lack of in vivo evidence of endothelial cell infection in
dengue cases is in contrast to the well-documented infection
of endothelial cells in hantavirus pulmonary syndrome, in
which pulmonary capillary infection is associated with in-
creased vascular permeability (46). Thus, other mechanisms
controlling sVEGFR2 levels may be more important in vivo
than the direct viral mechanism suggested by our in vitro data.
It is possible that the effects on endothelial cells in vivo may be
an indirect consequence of the interaction between virus and
other cell types, as reported in other viral hemorrhagic dis-
eases. In a rhesus model of Ebola virus infection, it has been
demonstrated that factors released from infected macrophages
enhanced vascular permeability (13, 14). Unlike sVEGFR2,
exposure to live virus has no effects on the production of
sVEGFR1 by endothelial cells. This suggests that the elevated
sVEGFR1 levels in DHF patients may reflect indirect effects of
virus on endothelial cells or may be secondary to host immune
responses. Alternatively, the elevated sVEGFR1 level may re-
flect activation of other cell types known to express VEGFR1,
particularly macrophages, during viral infection (38). These
findings underscore the need for additional studies to identify
target cells that are infected with dengue virus in vivo. Such
studies are challenging, since the mortality rate of DHF is
significantly lower than those of other viral hemorrhagic dis-
eases and deaths typically occur late in infection (4).
The lack of a relevant animal model that mimics the pattern
of plasma leakage in DHF has not allowed an in vivo experi-
ment to precisely delineate the role of VEGF relative to other
cytokines reported to be elevated in DHF, such as IL-2, IFN-	,
tumor necrosis factor alpha, and IFNs, in plasma leakage (6,
19, 41). However, the temporal pattern of VEGF and its
known biological effects argue for its role as a mediator in-
volved in plasma leakage in DHF. Unlike these proinflamma-
tory cytokines with peak levels occurring early in the course of
the disease prior to plasma leakage, the peak levels of plasma
VEGF occurred simultaneously with plasma leakage. Further-
more, increased vascular permeability induced by VEGF can
occur in the absence of overt inflammation, as evidenced by its
role during embryogenesis (10, 12). This effect is consistent
with the unique characteristics of plasma leakage in DHF,
which is transient and occurs without significant tissue inflam-
mation (7). The levels of VEGF in DHF cases were compara-
ble to those reported in conditions with clinically significant
plasma leakage and were much higher than the elevated levels
reported in conditions associated with localized vasculogenesis
(1, 2, 43). The association between plasma leakage and the
elevation of free VEGF, together with minimal tissue pathol-
FIG. 7. Model for regulation of VEGF activity by dengue virus and dengue virus-specific immunity. Preexisting nonneutralizing antibody may
enhance dengue virus uptake, resulting in a greater viral load. Dengue virus down-regulates the production of sVEGFR2 either directly by
interaction with endothelial cells or indirectly via interaction with other cell types. The reduction in sVEGFR2 production results in decreased
plasma sVEGFR2 and increased free, biologically active VEGF. VEGF may also be produced by activated dengue virus-specific T cells. A
concurrent increase in surface expression of VEGFR2 may enhance endothelial cell responsiveness to VEGF stimulation. The combination of
increased biologically active VEGF and enhanced receptor responsiveness results in increased vascular permeability and clinical plasma leakage.
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ogy in DHF, supports a role for VEGF in the regulation of
vascular permeability in this condition.
DHF occurs mostly in individuals previously infected with
dengue virus of another serotype. Preexisting dengue virus-
specific antibody may enhance the uptake of dengue virus
during secondary infection, resulting in a greater viral load,
which according to our model would lead to decreased
sVEGFR2 levels and enhanced VEGF activity (Fig. 7) (16, 18,
29). A greater viral load may also lead to the exaggerated
activation of both innate and adaptive immunity. In particular,
T cells have been shown to produce VEGF, and VEGF has
been reported to induce IFN-	 production by T lymphocytes
(30, 32). Activation of dengue virus-reactive memory T cells
that cross-recognize another dengue virus serotype may there-
fore contribute to the elevated VEGF and IFN-	 levels ob-
served in DHF patients.
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